• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

IQHQ Broadens Massachusetts Life Science Portfolio With Acquisition of Innovation Park in Andover

Share:

May 25, 2020

IQHQ, Inc., a premier life sciences real estate development company, today announced that in an off-market transaction, it has acquired Innovation Park, an approximately 200,000 square foot campus on the 495 Corridor in Andover, Massachusetts. The strategic acquisition will complement IQHQ’s portfolio of downtown assets, and it will meet the increasing demand by large institutions for state-of-the-art office and lab space in both downtown Boston and in the surrounding suburbs.

This growing trend is illustrated by Innovation Park’s newest tenants – UMass Lowell and Ora, Inc., which have signed long-term leases with IQHQ. Colliers represented IQHQ for the transaction, and the purchase price was not disclosed. TRIA Architects has been retained to redesign the site as part of IQHQ’s strategic repositioning plan.

“The acquisition of Innovation Park supports our vision for Massachusetts by expanding our footprint outside of downtown Boston and into the surrounding Andover medical innovation and life science cluster,” said Tracy A. Murphy, President of IQHQ. “We are pleased to welcome UMass Lowell and Ora as our first tenants. Through our redesign, we will enhance the campus to meet the needs of future tenants that are seeking premier office and lab space in Greater Boston.”

Since 2016, there has been approximately 2 million square feet of new demand for suburban lab space in Greater Boston. The acquisition of the Innovation Park campus in Andover is complementary to IQHQ’s portfolio of downtown Boston assets including 109 Brookline Avenue, a 285,000 square-foot lab and office building near the Longwood Medical Area, and the Fenway Center project, a state-of-the-art development that will include lab, office, and ground level retail space. Following IQHQ’s successful completion of a $770 million capital raise earlier this year, the REIT has been rapidly expanding its portfolio to support its strategy of investing in cutting-edge life science projects in top innovation hubs.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“It is exciting to see IQHQ expand and diversify its life science portfolio in Massachusetts, and it is encouraging to see continued investment in the Greater Boston biotech sector in the middle of the pandemic that has had such an impact on our lives and economy,” said Robert K. Coughlin, President & CEO of MassBio. “As the top life sciences cluster in the world, Massachusetts is playing a critical role in the search for new treatments for COVID-19, and as this deal illustrates, the biotech industry will also play a major role in our economic recovery.”

Located at 4 Corporate Drive in Andover, IQHQ plans to update the Innovation Park property. The redesign will add new amenities including a first-class café with indoor and outdoor seating, a fitness center also with both indoor and outdoor workout areas and common area improvements.

Source: BioSpace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Welltok Adds Four New Digital Programs, Atrium Health Adopts Butterfly’s Handheld Ultrasound and More Digital Health DealsWelltok Adds Four New Digital Programs, Atrium Health Adopts Butterfly’s Handheld Ultrasound and More Digital Health Deals
  • Olive Lands $51M to Power AI-powered Digital Employee PlatformOlive Lands $51M to Power AI-powered Digital Employee Platform
  • FDA panel rejects Pain Therapeutics’ abuse-deterrent opioid RemoxyFDA panel rejects Pain Therapeutics’ abuse-deterrent opioid Remoxy
  • Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in IndiaAjinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India
  • Femtech Market has Potential But Struggles to Score Investor DollarsFemtech Market has Potential But Struggles to Score Investor Dollars
  • Lodo Therapeutics Acquires Conifer Point PharmaceuticalsLodo Therapeutics Acquires Conifer Point Pharmaceuticals
  • Adaptas Solutions Completes Acquisition of Applied Kilovolts and Analytical Instrumentation Business from L3Harris TechnologiesAdaptas Solutions Completes Acquisition of Applied Kilovolts and Analytical Instrumentation Business from L3Harris Technologies
  • Unite Us Launches New, Secure Chat FeatureUnite Us Launches New, Secure Chat Feature

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications